Trial reportBMC pulmonary medicine2026
Therapeutic effects of oxygen inhalation for obstructive sleep apnea patients with high carotid body chemosensitivity.
Trial report in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundObstructive sleep apnea (OSA) is a heterogenous disease with several pathophysiological phenotypes; therefore, treatment must be tailored accordingly. This study aimed to explore the therapeutic effects of oxygen (O2) inhalation in OSA patients with high carotid body (CB) chemosensitivity (hCBC).
methodsCB chemosensitivity (CBC) was measured with the Dejours test in this single-arm clinical trial, and hCBC was defined as a respiratory rate reduction of > 12% after inhalation of pure O2. Subjects with hCBC were enrolled for two overnight polysomnographies, the first one with air inhalation and the second one with O2 inhalation. The morning blood pressure after awakening was measured along with heart rate variability (HRV) metrics, including high-frequency power (HF), low-frequency power (LF), and the LF/HF ratio.
resultsA cohort of 74 OSA patients exhibiting hCBC were enrolled. The mean CBC, as measured by the Dejours test, was 17.4 ± 4.2%. The apnea–hypopnea index (AHI) was significantly lower when the patients inhaled O2 (19.92 ± 13.49 events/h) compared to when they inhaled air (26.53 ± 12.18 events/h; P = 0.003). O2 inhalation also improved the nadir pulse O2 saturation (SpO2) (75.81 ± 12.44% vs. 83.91 ± 6.97%, P = 0.0021), decreased the blood pressure in the morning from 107.3 ± 8.32 mmHg (air inhalation) to 94.08 ± 5.93 mmHg (O2 inhalation), and lowered the HRV, as demonstrated by changes in the natural logarithm-transformed values of LF (8.933 ± 1.472 ln ms2 vs. 6.231 ± 2.136 ln ms2, P < 0.001), and the LH/HF ratio (1.381 ± 0.431 vs. 1.124 ± 0.319, P = 0.025).
conclusionO2 inhalation decreased symptom severity in OSA patients with hCBC as well as alleviated cardiovascular complications related to OSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.